PTO/SB/25 (05-03)

Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A PENDING SECOND APPLICATION	d d

In re Application of: Ales Franc et al.
Application No. 10/549.296

Application No. 10/549,296

Filed: September 15, 2005

For: PHARMACEUTICAL COMPOSITION CONTAINING PLATINUM COMPLEX AS ACTIVE SUB

The owner*, Pliva-Lachema A.S., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 12305337

filed on 03-12-2009 of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filled prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclatimed in whole or terminally disclaimed ander 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutor term as shortened by any terminal disclaimer filled prior to its grant.

Check either box 1 or 2 below, if appropriate.

1.		For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency etc.), the undersigned is empowered to act on behalf of the organization.
	L	etc.) the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. X The undersigned is an attorney or agent of record.

Nade-Alia 10(7(10)

Nader A. Abadir

Typed or printed name

845-359-7700

Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SE/96 may be used for making this statement. See MPEP § 324.

This collection of mitomation is required by 37 CFR 1.371. The information is required by detain or retain a benefit by the public width in it is life (see by the USFD) to process, an application. Confidentability groupment by 55 US x 12 and 37 CFR 1.14. This collection is estimated to take 12 mitudes to completely including an application. Confidentability the completes approached from the trib 10 CFR 1.14. This collection is estimated to take 12 mitudes to completely including account of the trib 10 CFR 1.14. This collection is setting upon the study data 24. Any occurrent or other account of the trib 10 central or other accounts of the 10 CFR 1.14. This collection is setting and the set of the 10 CFR 1.14. This collection is setting and the 10 CFR 1.14. This collection is setting and the 10 CFR 1.14. This collection is collected by the 10 CFR 1.14. This collection is setting and